
Trevi Therapeutics, Inc.
87
Recent developments focus on Trevi Therapeutics' clinical progress with Haduvio, financial results for Q3 2026, and ongoing preparations for pivotal Phase 3 trials.
- Trevi Therapeutics reported third quarter 2026 financial results, including a net loss of $21.45 million and strong liquidity with over $300 million in current assets as of September 30, 2026 [N2][S2].
- The company held $27.85 million in cash and equivalents and $271.56 million in short-term investments at the end of Q3 2026, resulting in a current ratio of 38.86 and a cash ratio of 38.05, indicating strong liquidity [N2][S2].
- Trevi is advancing two pivotal Phase 3 trials for Haduvio in 2026: one for IPF-related chronic cough beginning in Q2 and another planned for the second half of the year [N1][N8].
- The company’s Chief Commercial Officer adopted a Rule 10b5-1 trading plan in August 2026 for stock option sales, expiring December 31, 2027 [S2].
- No material legal proceedings were reported as of the latest filings [S1].
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing treatments for chronic cough and related respiratory diseases. Its lead candidate, Haduvio, is in pivotal Phase 3 trials targeting chronic cough associated with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (ILD), and refractory chronic cough (RCC). The company operates in a competitive landscape with other pharmaceutical and biotech firms developing therapies for chronic cough and fibrosis-related conditions. Trevi maintains strong liquidity with over $300 million in current assets as of Q3 2026 and continues clinical development activities supported by recent public disclosures and earnings reports.
Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for chronic cough, notably advancing Haduvio in pivotal Phase 3 trials. The company reported a net loss of $21.45 million and strong liquidity with a current ratio of 38.86 as of September 30, 2026, according to its latest 10-Q filing [S2].
The company’s advancement of Haduvio into pivotal Phase 3 trials for chronic cough in IPF and RCC patients demonstrates clinical progress and potential to address unmet medical needs. Strong liquidity and recent capital raises provide financial resources to support ongoing development. Positive clinical data and regulatory milestones could enhance the company’s position in the chronic cough therapeutic area.
Trevi Therapeutics faces significant competition from larger pharmaceutical companies and other clinical-stage programs targeting chronic cough and fibrosis-related diseases. The company reported a net loss and operates without current product revenues, relying on successful clinical trial outcomes and regulatory approvals. Risks include clinical trial failures, regulatory delays, and competitive pressures that could impact development and commercialization prospects.
Trevi Therapeutics' moat is primarily based on its clinical-stage pipeline focused on chronic cough, particularly Haduvio, which is in pivotal Phase 3 trials. The company’s specialized focus on IPF-related and refractory chronic cough addresses unmet medical needs in a competitive but challenging therapeutic area. Its moat is supported by ongoing clinical development progress and regulatory engagement, though it faces competition from larger pharmaceutical companies with greater resources and alternative therapies in development.
• Competition Risk: The company faces competition from major pharmaceutical and biotechnology companies with greater resources and expertise, which may develop more effective or better-tolerated therapies before or more successfully than Trevi Therapeutics [S2].
• Clinical Development Risk: Success depends on the outcomes of pivotal Phase 3 trials for Haduvio; failure or delays in clinical trials could adversely affect the company’s prospects [N1][N2].
• Regulatory Risk: Obtaining FDA and other regulatory approvals is uncertain and may be impacted by competitor approvals or regulatory decisions [S2].
• Financial Risk: The company reported net losses and relies on capital markets and financing to fund operations; changes in market conditions or financing availability could impact liquidity [S2].
• Disclosure and Reporting Risk: Use of scaled disclosure accommodations may reduce transparency and affect investor analysis until eligibility ends in Q1 2027 [S2].
Business trends: Continued clinical development of Haduvio in pivotal Phase 3 trials targeting chronic cough in IPF and RCC patients, with a focus on addressing unmet medical needs in respiratory diseases.
Execution milestones: Initiation and progress of two pivotal Phase 3 trials in 2026, maintenance of strong liquidity to support operations, and regulatory engagement.
Key risks: Clinical trial outcomes, regulatory approval uncertainties, competitive pressures from larger pharmaceutical companies, and reliance on capital markets for funding.
Very high visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for chronic cough and related respiratory conditions.
- The company is advancing Haduvio, a drug candidate targeting chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease (ILD), as well as refractory chronic cough (RCC).
- Haduvio is in pivotal Phase 3 clinical trials, with two trials planned in 2026, one beginning in Q2 for IPF-related chronic cough and another in the second half of 2026.
- The company faces competition from major pharmaceutical and biotechnology companies developing treatments for chronic cough and related conditions, including competitors with approved or in-development P2X3 antagonists.
- Trevi Therapeutics reported a net loss of $21.45 million for the quarter ended September 30, 2026, with basic and diluted EPS of -$0.13 per share.
- As of September 30, 2026, the company held $27.85 million in cash and equivalents and $271.56 million in short-term investments, totaling $305.8 million in current assets against $7.87 million in current liabilities, resulting in a current ratio of 38.86 and a cash ratio of 38.05, indicating strong liquidity.
- The company uses scaled disclosure accommodations as a smaller reporting company but will lose eligibility starting Q1 2027 due to market capitalization exceeding $700 million.
- No material legal proceedings were reported as of the latest filings.
- The company’s Chief Commercial Officer adopted a Rule 10b5-1 trading plan in August 2026 for stock option sales.
- Recent news coverage includes multiple earnings call transcripts and financial results reports through 2026, highlighting clinical progress and financial status.
- The company’s development pipeline includes Haduvio and other early-stage programs, with ongoing clinical trials and regulatory activities.
- The company’s financial figures and liquidity ratios are summarized from the latest SEC filings and provided for informational purposes only.
Generated 2026-11-10
- N1
- N3
- S1 | 2026-03-17 | 10-K
- S2 | 2026-11-09 | 10-Q
- N1 | 2026-11-10 | www.nasdaq.com | Trevi Therapeutics (TRVI) Q3 2026 Earnings Call Transcript | https://www.nasdaq.com/articles/trevi-therapeutics-trvi-q3-2026-earnings-call-transcript
- N2 | 2026-11-10 | www.nasdaq.com | Trevi Therapeutics, Inc. Reports Third Quarter 2026 Financial Results | https://www.nasdaq.com/articles/trevi-therapeutics-inc-reports-third-quarter-2026-financial-results
- N3 | 2026-08-07 | www.nasdaq.com | Trevi Therapeutics Q2 Earnings Call Highlights | https://www.nasdaq.com/articles/trevi-therapeutics-q2-earnings-call-highlights
- N4 | 2026-07-23 | www.nasdaq.com | Serina Appoints Simon To Board; Concludes Dosing In Phase 1b For Parkinson's Therapy SER-252 | https://www.nasdaq.com/articles/serina-appoints-simon-board-concludes-dosing-phase-1b-parkinsons-therapy-ser-252
- N5 | 2026-06-20 | www.nasdaq.com | 5 Biotech Stocks That Delivered Triple-Digit Gains - SYRE Up 400%, BFLY Up 300% & More | https://www.nasdaq.com/articles/5-biotech-stocks-delivered-triple-digit-gains-syre-400-bfly-300-more
- N6 | 2026-06-03 | www.nasdaq.com | Trevi Therapeutics Is Up 100%, Pivotal bioVenture Adds Anyway. Here's Why That Matters. | https://www.nasdaq.com/articles/trevi-therapeutics-100-pivotal-bioventure-adds-anyway-heres-why-matters
- N7 | 2026-05-09 | www.nasdaq.com | Trevi Therapeutics Maps Haduvio Chronic Cough Push, Sees Cash Runway Into 2030 | https://www.nasdaq.com/articles/trevi-therapeutics-maps-haduvio-chronic-cough-push-sees-cash-runway-2030
- N8 | 2026-05-06 | www.nasdaq.com | Trevi Reports Q1 Results, To Begin Phase 3 Trial Of Haduvio In IPF-related Chronic Cough In Q2 | https://www.nasdaq.com/articles/trevi-reports-q1-results-begin-phase-3-trial-haduvio-ipf-related-chronic-cough-q2
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


